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Summary Glutathione S-transferase (GST) isoenzyme composition, isoenzyme quantities and enzymatic
activity were investigated in benign (n = 4) ovarian tumours and malignant ovarian tumours, before (n = 20)
and after (n = 16) chemotherapy. Enzymatic activity of GST in cytosols was measured by determining
1-chloro-2,4-dinitrobenzene conjugation with glutathione, cytosolic GST subunits were determined by wide
pore reversed phase HPLC, using a S-hexylglutathione-agarose affinity column, and isoelectric focussing. Both
GST activity and GST pi amount were not related to histopathologic type, differentiation grade, or tumour
volume index in untreated malignant tumours. GST isoenzyme patterns were identical in benign tumours and
malignant tumours before and after platinum/cyclophosphamide chemotherapy, while GST pi was the
predominant transferase. Mean GST activity and GST pi amount were decreased (P< 0.05) in malignant
ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant
tumours. No relation was found in untreated ovarian tumours between GST pi amount and response to
platinum/cyclophosphamide chemotherapy. Thus, within the limitations of the current study no arguments
were found for a role of GST in in vivo drug resistance of malignant ovarian tumours to platinum/
cyclophosphamide chemotherapy.
Ovarian cancer is the fourth most frequent cause of cancer
death in women and the gynaecological cancer with the
highest mortality (Piver et al., 1991). The primary scheme for
the treatment of patients with advanced ovarian carcinoma
consists nowadays of cytoreductive surgery followed by
systemic chemotherapy with platinum and cyclophosphamide
containing combination regimens (Ozols & Young, 1991).
Despite response rates of 50-80% to chemotherapy the
above scheme results in only 15 to 20% long term survivors
(Thigpen et al., 1989; Ozols & Young, 1991). These clinical
data indicate, that in ovarian cancer intrinsic and acquired
drug resistance occurs to platinum and cyclophosphamide
containing regimens. In cell lines numerous mechanisms that
can contribute to resistance to cisplatin have been identified,
such as changes in membrane permeability, the ability to
remove cytotoxic lesions from DNA, and changes in detoxi-
fication pathways (Andrews & Howell, 1990). With regard to
cyclophosphamide and other anticancer drugs of the alkylat-
ing class, numerous studies point to the likelihood that
changes in GST isoenzyme composition and quantity contri-
bute in an important way to the resistance of tumour cells
(Waxman, 1990).
The aim of this study was to identify and quantify GST
isoenzymes in benign and malignant tumours of the ovary,
before and after chemotherapy and to relate the levels of
these enzymes in untreated tumours to response of these
tumours to chemotherapy. GSTs are a family of multifunc-
tional cytosolic proteins that function as important enzymes
of detoxification by catalyzing the conjugation of electro-
philic compounds to glutathione, and the non-covalent bind-
ing of various lipophilic compounds (Boyer, 1989). In man,
cytosolic GSTs have been divided into four major classes
termed alpha (basic), mu (neutral), pi (acidic) and theta
(Mannervik et al., 1985; Ogura et al., 1991). As these isoen-
zymes are known to have different substrate specifities, both
the total GST activity and the isoenyzme composition may
be important determinations of a tumours' ability to detoxify
different chemotherapeutic agents (Mannervik & Danielson,
1988). In numerous human tumour cell lines resistant to
cisplatin an enhanced GST content has been described, as
well as in human tumour cell lines resistant to alkylating
agents (for a review, see Meyer et al., 1990a; Teicher et al.,
1991; Ali-Osman et al., 1990; Ford et al., 1991). However,
almost no data are available on GST activity and isoenzyme
expression in tumours in vivo. In order to determine a possi-
ble role of GSTs in de novo and acquired resistance to
platinum/cyclophosphamide chemotherapy we measured in
this study the enzymatic activity, subunit composition and
tissue concentration of GSTs in benign ovarian tumours,
malignant ovarian tumours, and malignant ovarian tumours
after platinum/cyclophosphamide chemotherapy. The relation
between GST content of the untreated malignant tumours
with histopathologic type, differentiation grade and tumour
volume index, as well as the relation between the GST con-
tent of the malignant ovarian tumours with the clinical res-
ponse to chemotherapy was investigated.
Materials and methods
Human materials
Tumour specimens were obtained from patients operated at
cooperating hospitals in the northern part of the Netherlands
during the period 1989-1991. Tumour collection was super-
vised by a pathologist. After dissection samples were immed-
iately frozen in liquid nitrogen and stored at - 180°C until
further analysis. In two patients, tumour specimens were
obtained at first laparotomy and at second look operation
after chemotherapy. In one untreated patient with ovarian
cancer tumour specimens were obtained from the left and
right ovarian tumour. In two patients four, and in two
patients three specimens from different sites of the same
tumour were obtained.
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Pathological characteristics
The tumours were histologically classified according to the
World Health Organisation classification using paraffin
embedded tissue sections (Serov et al., 1973). One section per
cm tumour diameter was made to get a good overall impres-
sion of the tumour histology. Carcinomas were graded into
well, moderately, and poorly differentiated (Sobre et al.,
1982). Tumour volume index (percentage of malignant
epithelial tissue in tumour specimen) was measured in the
paraffin embedded sections. The tumour volume index was
measured by a point counting technique, using a 42-point
grid placed on a projection microscope at a magnification of
200-fold as described by Baak (Baak et al., 1988).
Classification of response to chemotherapy
Patients were defined as having a complete response (CR),
when a second look operation no pathologic evidence of
tumour was found, as having a partial response (PR), when
at second look operation pathologic evidence of tumour was
found, and tumour load was diminished (>50%) in com-
parison to residual tumour after first operation, as having
stable disease (SD), when at second look operation tumour
load was comparable to residual tumour size after first oper-
ation, and as having progressive disease (PD), when during
the course of chemotherapy at physical examination growing
tumour masses were found.
HPLC separation andquantification ofGST subunits and
determination ofGST activity
All actions were performed at 4°C, unless specified. All
tumours' aliquots (weights ranging from 37-650 mg) were
homogenised in 3.0 ml of Tris/HCI (25 mM, pH 7.4), using an
ultra-turrax. To avoid contamination by connective tissue,
the epithelium of the cystadenomas was dissected away from
the cyst wall and used for further analysis. Cytosols were
prepared by 90 min centrifugation at 110,000g. Cytosolic
GST was purified as described previously (Bogaards et al.,
1989). In brief a fixed amount of cytosol was applied to a
2 ml S-hexylgluthathione-agarose affinity column, washed
with 16 ml buffer containing 0.4 M NaCl, and eluted in the
same buffer containing 5 mM of S-hexylglutathione. The
eluates preceding the S-hexylglutathione alpha eluate were
checked for GST activity, and usually contained less than
5% of the total applied enzymatic activity. The eluate was
concentrated to approximately 0.2 ml, using a centricon
PM 10 ultrafiltration tube (Amicon, Danvers, USA), and
100 gLI was applied to wide pore reversed phase HPLC
(Vydac 105 TP 250 x 4.3 mm column). The subunits were
eluted with a gradient of acetonitrile in water, both contain-
ing 0.1% trifluoroacetic acid (from 40 to 50% acetonitrile in
18 min, followed by a further increase to 53% in 5 min and
isocrating elution for another 7 min). Detection was at
214 nm, while peak integration was performed using Nelson
analytical software. Concerning the method of quantification,
it should be noted that possible theta class isoenzymes pres-
ent in tumour tissues are not observed using this method,
since they do not bind to the affinity matrix and show almost
no enzymatic activity towards 1-chloro-2,4-dinitrobenzene
(CDNB).
Human GST isoenzymes used for reference and quantifica-
tion purposes was purified from a human placenta by means
of S-hexylglutathione affinity chromatography and chormato-
focusing, as described previously (van Ommen et al., 1990).
For isoelectric focusing, a Pharmacia Phastsystem was used
(pH range 3-9 precoates). Enzymatic activity of GST (con-
jugation of CDNB with glutathione) was performed accord-
ing to Habig (Habig et al., 1974).
Statistics
Statistical analysis of the distribution of tumour volume
index, GST activity, and GST pi levels in the different groups
was performed with the unpaired Student's t-test. Rank cor-
relations were calculated by the method of Spearman. Only
p-values<0.05 were considered significant.
Results
Patients characteristics
Tumour specimens from 40 patients were obtained. Four
patients had benign cystadenomas, and 20 patients had un-
treated ovarian adenocarcinoma (two patients FIGO stage I,
18 patients FIGO stage III). In 16 patients tumour specimens
were obtained after Pt/Cy containing chemotherapy. For
specification of the chemotherapeutic regimens and response
to these regimens in these 16 patients, see Table I. Eight of
the 16 patients had residual disease at second look laparo-
tomy, performed within 1 month after the last course of
chemotherapy, and eight patients had recurrent disease after
a previous CR at second look laparotomy. Recurrence of
disease in these eight patients occurred after a mean period
of 19 months (range: 3-60 months). Treatment of these 16
patients with residual or recurrent disease after laparotomy
consisted of varying second line chemotherapy regimens.
Tumour histopathology, differentiation grade and tumour
volume index
For histopathologic type and differentiation grade of the
untreated tumours, see Figures 1 and 2. No differences were
found in mean tumour volume index in untreated ovarian
cancer (52.3%, SD: 23.5), residual disease (46.6%, SD: 28.3),
and in recurrent disease (44.25%, SD: 18.5).
Enzymatic GST activity in cytosol
For mean GST activity in the different groups, see Table II.
Although large interindividual variations were observed
(range in adenomas: 0.07-0.20 U mg-' cytosolic protein (cp),
in untreated adenocarcinomas: 0.03-0.52 U mg-' cp, and in
adenocarcinomas after chemotherapy: 0.05-0.58 Umg-' cp),
the mean specific GST activity towards conjugation of
CDNB in tumours after chemotherapy was decreased (P<
0.05) compared to untreated tumours. Expressed on the basis
of the tumour weight, the differences were less pronounced.
This is most likely due to a slight increase in the amount of
cytosolic protein per gram tissue in tumours after chemo-
therapy (results not shown). Mean GST activity was in-
creased (P<0.05) in untreated ovarian adenocarcinoma in
comparison to benign tumours. No differences were found in
Table I Chemotherapy used in patients with residual or recurrent
disease
Patients Chemotherapy Response
1 res.d CP (6x) PR
2 res.d CC (6x) PR
3 res.d CC (6x) PR
4 res.d CC (6x) PD
5 res.d CP (6x) PD
6 res.d CC (6x) SD
7 res.d CAP (3x) PR
8 res.d CC (5x) PD
9 rec.d CC (6x) CR
10 rec.d CC (9x) CR
11 rec.d CC (6x) CR
12 rec.d CC (6x), P/Vp (3x) CR
13 rec.d CC (Sx) CR
14 rec.d CC (6x) CR
15 rec.d CP (4x) CR
16 rec.d CC (6x) CR
Res.d., residual disease; rec.d., recurrent disease; PR, partial res-
ponse; PD, progressive disease; SD, stable disease; CR, complete
response; CC, cyclophosphamide, carboplatin; CP, cyclosphos-
phamide, cisplatin; CAP cyclophosphamide, adriamycin, cisplatin;
P/Vp, cisplatin i.v., etoposide i.p.; (nx) number ofcycles.932 A.G.J. VAN DER ZEE et al.
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tumour specimens were obtained before and after
chemotherapy the GST activity was higher after chemo-
therapy (0.16 vs 0.58 Umg-' cp), while in the other patient
the GST activity was lower (0.52 vs 0.18 Umg-' cp).
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Figure 1 Amount of GST pi (rg mg- cytosolic protein) in
different histopathologic type of untreated malignant ovarian
tumours. M, mucinous adenocarcinomas; SA, serous adenocar-
cinomas; AC, adenocarcinomas; CL, clear cell adenocarcinoma;
PA, papillary adenocarcinomas; SC, serous cystadenocarcinoma.
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Identification ofGSTsubunits
Reversed phase HPLC separation of the affinity column
eluate showed the subunit pi to be the predominant trans-
ferase present in all samples (Figure 3, lower panel). This was
confirmed both by comparison with HPLC chromatograms
of known mixtures of human liver GST (Figure 3, upper
panel), comparison with purified GST pi isoenzymes and by
co-elution of tumour transferases with purified GST pi. Iso-
electric focussing of the purified tumour GST isoenzyme
mixture, together with purified GST pi confirmed the acidic
nature of the predominant tumour GST (results not shown).
A minor subunit (<3% of total cytosolic GST) was detected
in most samples (Figure 3). Although not completely charac-
terised, the corresponding isoenzyme has a molecular weight
of ca. 27,000 dalton and a pl of 5.1. It possesses a rather low
specific activity towards CDNB (ca. 5 U mg-1). We have also
observed this subunit in human liver and placenta (results
not shown).
No differences in subunit composition were observed either
within the benign and malignant tumours, or between the
malignant tumours before and after chemotherapy.
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Quantification ofGSTpi subunits
The mean amounts of GST pi in the various groups are
shown in Table II. Similar to the effects observed with the
cytosolic GST activity, the mean GST pi amount per mg
cytosolic protein was lower (P<0.05) in the malignant
tumours after chemotherapy as compared to the untreated
tumours. When expressed relative to the tumour weight, the
50% decrease is not significant due to the large variation of
3
Figure 2 Amount of GST pi (,ugmg-' cytosolic protein) in
relation to differentiation grade of untreated malignant ovarian
tumours. Differentiation grade 1, well differentiated; 2, moder-
ately differentiated; 3, poorly differentiated.
Table 11 Tumour volume index, enzymatic GST activity and amount
ofGST pi in adenomas, untreated ovarian cancer, and ovarian cancer
after chemotherapy
Tumour n TVI GST act. GSTpi
Benign 4 0.14±0.05 1.50±0.44
Untr. ca. 20 52.3±23.5 0.26±0.16a 3.61±2.21a
Res./rec. 16 47.0±23.3 0.18±0.12b 1.78± 1.38b
TVI, mean tumour value index±s.d.; GST act., mean GST activity
(CDNB conjugation) in U mg-i cytosolic protein± s.d.; GST pi, GST
pi in ig mg- cytosolic protein±s.d.; Untr.ca., untreated cancer;
Res./rec., residual and recurrent disease; aHigher (P< 0.05) in com-
parison to benign tumours; bLower (P<0.05) in comparison to
untreated malignant tumours.
mean GST activity in benign tumours and mean GST
activity in residual or recurrent tumours after chemotherapy.
In the four patients from whom tumour specimens were
obtained from respectively three and four different sites of
the tumours the variation within these tumours was relatively
small. The specific activity measured in cytosols in the
different specimens always showed a standard deviation of
less than 18%, both for untreated tumours, and tumours
after chemotherapy. In one of the two patients from who
Elution time (min)
Figure 3 HPLC separation of glutathione S-transferase subunits,
allowing for identification and quantification of the various sub-
units. Upper panel: Human GST subunits as present in liver.
Lower panel: Elution profile of GST subunits purified from a
tumour sample.
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GST pi amount in the individual tumours in the different
groups (adenomas, range: 0.85-1.77 igmg'I cp; untreated
adenocarcinomas, range: 1.40-9.21 igmg-' cp; adenocar-
cinomas after chemotherapy, range: 0.45-5.68). The intra-
tumour variation in the four patients from whom tumour
specimen were obtained from respectively three and four
different sites was relatively small. The amount of GST pi
measured in cytosols in the different specimens always
showed a standard deviation of less than 24%, both for
untreated tumours, and tumours after chemotherapy. In the
tumour specimens from both patients from whom tumour
specimens were obtained before and after chemotherapy the
amount of GST pi was lower after chemotherapy in com-
parison to before chemotherapy (4.51 vs 9.21 .Lg GST pi
mg-' cp and 1.85 vs 2.68 ,g GST pimg-' cp).
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Relation between activity andsubunit composition
Figure 4 presents the relation between the cytosolic GST
activity (CDNB conjugation) and the amount of GST pi in
cytosol. A correlation coefficient of 0.83 was calculated for
the total amount of samples. When separated into untreated
tumours and tumours after chemotherapy, the correlation
becomes less pronounced (0.79 and 0.70, respectively). The
specific activity, as calculated from the slope of the regression
line, is 51 nmol of CDNB conjugated per mg of GST pi
(66 U mg-'), as purified in our laboratory.
Relations between GSTpi amount/histopathologic type,
differentiation grade and tumour volume index
No relation was found between GST pi amount and histo-
pathologic type, differentiation grade and tumour volume
index of the untreated tumours (Figure 1, 2, and 5). Tumours
after chemotherapy were not included to rule out possible
influence of chemotherapy on GST pi amount.
GSTpi amount and response to chemotherapy
Table III shows the amount of GST pi mg-' cp, FIGO stage,
chemotherapeutic regimen, and response to chemotherapy in
20 patients in which GST pi was measured in tumour speci-
mens before treatment. Two of these patients did not receive
chemotherapy because of FIGO stage I, one patient was
considered too old, and three patients received monotherapy
because of high age. In two of the patients with PD during
first line chemotherapy a second look laparotomy was per-
formed to make another effort for debulking the tumour
load. Figure 6 presents the relation between the GST pi
amount mg-' cp and response to platinum/cyclophospha-
mide chemotherapy. No rank correlation was found. In the
Figure 5 Amount of pi (fg mg-' cystolic protein) in relation to
tumour volume index of untreated malignant ovarian tumours.
r = 0.25, n.s.
Table III Amount ofGST pi, FIGO stage, chemotherapeutic regimen
and response to chemotherapy
Pts. FIGO stage Chemotherapy GSTpi Response
1 IAI 1.40
2 III C/C (6x) 3.78 PR
3 III 1.51
4 III C/C (6x) 5.50 SD
5 III C/C (6x) 5.21 CR
6 IAI - 2.70
7 III C/P (6x) 5.43 CR
8 III C/C (6x) 8.45 PR
9 III C/C (5x) 9.21 PD
10 III C/C (4x) 3.28 PD
11 III C/C (5x) 2.61 PD
12 III Cy (lx) 3.60 PD
13 III CC (6x) 0.31 PR
14 III Cy (4x) 2.39 PD
15 III Cy (5x) 5.36 SD
16 III CC (4x) 3.15 CR
17 III CC (6x) 2.14 PR
18 III CP (lx) 1.85 PD
19 III CC (4x) 3.35 CR
20 III CC (5x) 2.68 PD
Pts., patients; GST pi, gsg mg-l cytosolic protein; CC, cyclophos-
phamide, carboplatin; CP, cyclophosphamide cisplatin; Cy, cyclophos-
phamide; CR, complete remission; PR, partial response; SD, stable
disease; PD progressive disease.
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Figure 4 The relations between the enzymatic activity towards
CDNB of cytosolic glutathione S-transferase and the amount of
GST pi in the various tumour samples (- = untreated cancers,
A = residual disease, 0 = recurrent disease).
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Figure 6 Relation between the quantity of glutathione S-trans-
ferase (amount of GST pi) and the response to platinum/cyclo-
phosphamide treatment.
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group of eight patients with residual disease, from which
tumours were obtained after chemotherapy, progressive
disease occurred in all patients despite second and sometimes
third line chemotherapy (various regimens). In the group of
eight patients with recurrent disease after first line
chemotherapy progressive disease occurred in five patients
during second line chemotherapy (various regimens), one
patient was lost for follow-up, and complete remission after
second line chemotherapy occurred in two patients (one
patient received six courses of methotrexate, and one patient
six courses of cisplatin/cyclophosphamide). Recurrence of
disease after first line chemotherapy in these last two patients
occurred after 4 and 5 years, respectively. In the patients with
residual or recurrent disease no relation was found between
GST pi levels in the tumour specimens and response to
second line chemotherapy.
Discussion
Response to platinum/cyclophosphamide chemotherapy in
ovarian cancer is quite variable. Well known prognostic fac-
tors in ovarian cancer are FIGO stage, differentiation grade,
age of the patient, histopathologic type, residual tumour load
after first laparotomy, morphometrical features and cellular
DNA content (Baak et al., 1988). However, even within a
group of patients with the same prognostic factors the res-
ponse to chemotherapy is unpredictable. Therefore additional
markers are needed to predict response to chemotherapy.
Recently, a positive correlation between the enzymatic
activity of GST and drug resistance to platinum and/or
alkylating agents has been reported in cell lines (Lewis et al.,
1988; Meyer et al., 1990a; Teicher et al., 1991; Ali-Osman et
al., 1990; Ford et al., 1991). Cell lines with in vitro acquired
resistance or cell lines derived from resistant tumours showed
higher GST levels than their non-resistant equivalents. Fur-
thermore, expression of GST genes in cell lines led to a
resistance against these types of compounds (Moscow et al.,
1989a). These observations suggest a role of GST in acquired
drug resistance, possibly by means of an increased gluta-
thione conjugation of antineoplastic agents or their reactive
intermediates. Repeated treatment of patients with malignant
ovarian tumours with platinum and/or alkylating agents may
induce overexpression of GST. In this study both GST
enzymatic activity and GST pi (which was the dominant
GST isoenzyme) level were lower after treatment with plati-
num/cyclophosphamide in comparison to untreated tumours.
However, as in most in vivo studies, also our study is charac-
terised by several complicating factors. Even in the patients
with residual disease after chemotherapy the period between
last course of chemotherapy and time of excision of the
tumour specimen was at least 4 weeks, and therefore a possible
transient rise in GST levels may be missed. Our series is
small, and the range of histological types of tumours is wide.
In only two patients tumour specimens were obtained before
and after chemotherapy. GST pi levels were lower after
chemotherapy in these two patients with paired specimens,
while in one patient GST activity was lower, and in the other
GST activity was higher after chemotherapy.
Lower GST activity in malignant ovarian tumours after
chemotherapy is in agreement with the findings of Djuric et
al. who found decreased activity of GST in malignant ovar-
ian tumours after platinum/cyclophosphamide chemotherapy
(Djuric et al., 1990). In their study isoenzyme patterns of
GSTs, and relations of GST pi level to response to chemo-
therapy were not determined.
In this study the acidic pi class GST was the most abun-
dant GST form in benign ovarian tumours, and in malignant
ovarian tumours, as was found by others in different human
tumours, including lung, colon, bladder, and breast tumours
(Di Ilio et al., 1985; 1988; Carmichael et al., 1988; Shea et al.,
1988; 1990). Lewis et al. (1989) described extremely high
levels of the alpha class subunit in one malignant ovarian
tumour, but this finding could not be confirmed by us in 36
malignant ovarian tumours. The isoenzyme composition in
the residual and recurrent malignant ovarian tumours after
platinum/cyclophosphamide chemotherapy did not change in
comparison to the untreated malignant ovarian tumours. No
other data exist in literature regarding GST isoenzyme pat-
terns in malignant human tumours before and after chemo-
therapy. GST pi levels correlated well with GST activity in
treated and untreated ovarian tumours (Figure 4). The one
outlying point belongs to the patient with specimens obtained
before and after chemotherapy, higher GST activity and
lower GST pi level after chemotherapy. The isoenzyme pat-
tern of the residual tumour of this patient showed no marked
differences as compared to the corresponding primary
tumour. Although one explanation for the disparity in GST
activity and GST pi level may be a 'missed' isoenzyme in the
HPLC assay, in our opinion this observation cannot be
explained by the presence of major amounts of other isoen-
zymes.
Mean GST pi level was higher (P<0.05) in untreated
malignant ovarian tumours compared to benign tumours.
This is in agreement with the findings for other human
tumours, such as lung, colon, bladder, and breast tumours,
where GST pi levels were higher in malignant tissue in
comparison to the adjacent benign tissues (Shea et al., 1988;
Moscow et al., 1989b; Howie et al., 1990). However, mean
GST pi level was equal in benign ovarian tumors and malig-
nant ovarian tumours after platinum/cyclophosphamide
chemotherapy.
Above mentioned in vitro studies suggested a relation in
GST pi levels and resistance to chemotherapy. Uncertainty
remains however, as to whether data describing mechanisms
of resistance in vitro are relevant in human tumours. In
earlier work we described no changes in P-glycoprotein and
lower topoisomerase II in malignant ovarian tumours after
platinum/cyclophosphamide chemotherapy in comparison to
untreated tumours (van der Zee et al., 1991). In the current
study no relation could be found between GST pi levels in
untreated malignant ovarian tumours and response of these
patients to platinum/cyclophosphamide chemotherapy. So far
no further data exist in literature on GST pi levels in
tumours and response to platinum/cyclophosphamide chemo-
therapy. In patients with human breast tumours no relation
was found between GST pi expression and in vitro chemosen-
sitivity to doxorubicin (Keith et al., 1990), and in another
study in human breast tumours no relation was found
between GST pi content and other prognostic factors (Shea
et al., 1990). Kim et al. also did not find GST pi expression
as an indicator of response to adriamycin in 15 human
tumours (Kim et al., 1991). Lower levels of GST pi after
platinum/cyclophosphamide chemotherapy and no relation of
GST pi levels with response to platinum/cyclophosphamide
chemotherapy both do not suggest an important role of GST
pi in in vivo drug resistance. However, for the assays, as used
in our study, homogenisation of tissue is required. In this
way small subpopulations of tumour cells with high GST pi
levels between large populations of tumour cells with low
GST pi levels can be missed. Terrier et al. found hetero-
geneity of expression of GST pi among different normal
human tissues and also heterogeneity of GST pi expression
within the same tissue using an immunohistochemical detec-
tion technique (Terrier et al., 1990). Recently Rahilly et al.
also found heterogeneity of GST isoenzyme expression in
benign and untreated malignant ovarian tumours (Rahilly et
al., 1991). Perhaps the small subpopulations with high GST
pi levels will eventually determine the response of the tumour
to chemotherapy, and therefore, although not in favour for a
significant role for GST pi as marker of clinical drug resis-
tance, out study does not rule out a possible role of GST
isoenzymes in clinical drug resistance. In the future deter-
mination of GST pi levels with HPLC as well as an indirect
immunohistochemical technique, using a polyclonal antibody
against GST pi, can elucidate this problem. Another compli-
cating factor in evaluating GST and glutathione levels in
tumour specimens is the fact, that GSTs and glutathione are
parts of a complicated detoxification system, of which
glutathione and GSTs steady states are often used to deter-GLUTATHIONE S-TRANSFERASES IN OVARIAN TUMOURS 935
mine the level of this detoxification system, as was done for
GSTs in the current study. Insight in the kinetics of
glutathione and GST status should give a more dynamic
representation of the continuous availability of this defence
(Meijer et al., 1990b). However, our findings, that GST pi
levels in untreated tumours showed no relation to response to
chemotherapy, and that GST pi levels were decreased in
malignant tumours after platinum/cyclophosphamide chemo-
therapy make the eventual use in clinical trials of inhibitors
of GST enzymes, such as ethacrynic acid or piriprost as
modulation strategy in enhancing sensitivity of malignant
tumours to platinum/cyclophosphamide chemotherapy not
very promising (Schilder et al., 1990). Our study indicates
that other in vitro well established mechanisms of drug resis-
tance, such as decreased cell membrane transport of plati-
num, other detoxification pathways, and changes in repair of
platinum DNA adducts, need to be evaluated in vivo, as was
done for GSTs in the present study.
We greatly acknowledge all participating pathologists and gynae-
cologists for their help in collecting tumour samples.
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